DXCM logoDXCM
Dexcom Inc

9,904
Loading...
Loading...
News
all
press releases
DexCom Stock Slumps 10% After Hunterbrook Media Investigation Raises Concerns About Its G7 Device
Hunterbrook Capital said on Thursday that it has a short position in DXCM stock based on Hunterbrook Media’s reporting, which stated that after inaccurate readings from Dexcom’s G7 continuous glucose monitor device, some diabetics are ending up in the ICU or dead.
Stocktwits·9h ago
News Placeholder
More News
News Placeholder
Investing in the Age of Longevity: Silver Economy Stocks in Focus
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
Zacks·18d ago
News Placeholder
Why Is DexCom (DXCM) Down 7% Since Last Earnings Report?
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·22d ago
News Placeholder
Dexcom Announces Upcoming Conference Presentations
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: The 2025 Wells Fargo Healthcare Conference on...
Business Wire·25d ago
News Placeholder
DexCom Expands Access and Innovation While Balancing Headwinds
DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.
Zacks·1mo ago
News Placeholder
Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data
TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.
Zacks·1mo ago
News Placeholder
Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?
ABT's Diabetes Care sales surge 19.6% in Q2, fueled by strong U.S. demand and new OTC approvals for its CGM systems.
Zacks·1mo ago
News Placeholder
DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise
DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.
Zacks·2mo ago
News Placeholder
Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·2mo ago
News Placeholder
DexCom (DXCM) Q2 Earnings and Revenues Top Estimates
DexCom (DXCM) delivered earnings and revenue surprises of +6.67% and +3.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago

Latest DXCM News

View

Advertisement. Remove ads.

Advertisement. Remove ads.